Gary L. Davis
#142,519
Most Influential Person Now
Gary L. Davis's AcademicInfluence.com Rankings
Gary L. Davisphilosophy Degrees
Philosophy
#7491
World Rank
#10712
Historical Rank
Logic
#4536
World Rank
#5845
Historical Rank
Gary L. Davisbiology Degrees
Biology
#10160
World Rank
#13463
Historical Rank
Virology
#237
World Rank
#244
Historical Rank
Biochemistry
#1592
World Rank
#1724
Historical Rank
Download Badge
Philosophy Biology
Gary L. Davis's Degrees
- PhD Biochemistry University of California, Berkeley
- Doctorate Medicine University of California, San Francisco
Why Is Gary L. Davis Influential?
(Suggest an Edit or Addition)Gary L. Davis's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. (1998) (1334)
- Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa (1989) (1328)
- Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C (2003) (876)
- Significance of serum hepatitis C virus RNA levels in chronic hepatitis C (1993) (840)
- A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B (1990) (757)
- Projecting future complications of chronic hepatitis C in the United States (2003) (608)
- Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. (1989) (415)
- Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial (1997) (404)
- Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. (1993) (367)
- Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. (2000) (363)
- Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C (1997) (360)
- Factors predictive of a beneficial response to therapy of hepatitis C (1997) (336)
- The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. (1997) (333)
- Health‐related quality of life in chronic hepatitis C: Impact of disease and treatment response (1999) (333)
- Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. (2010) (321)
- Impact of interferon alfa‐2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C (2000) (294)
- Spontaneous reactivation of chronic hepatitis B virus infection. (1984) (282)
- Quantitative detection of hepatitis C virus RNA with a solid‐phase signal amplification method: Definition of optimal conditions for specimen collection and clinical application in interferon‐treated patients (1994) (218)
- Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. (1995) (214)
- Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect (2003) (214)
- Monitoring of viral levels during therapy of hepatitis C (2002) (208)
- Distribution of Hepatitis C Virus Genotypes Determined by Line Probe Assay in Patients with Chronic Hepatitis C Seen at Tertiary Referral Centers in the United States (1996) (207)
- Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. (1983) (207)
- Indications for liver transplantation. (2008) (198)
- Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease (2010) (198)
- Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C (2003) (197)
- Hepatocellular Carcinoma: Management of an Increasingly Common Problem (2008) (190)
- Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse. (2004) (187)
- Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse (2005) (182)
- Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: A report from the International Registry of Hepatic Tumors in Liver Transplantation (2007) (180)
- A randomized, open‐label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients (2005) (173)
- Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. (1994) (172)
- A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. (1990) (170)
- Hepatic adenoma and focal nodular hyperplasia: Clinical, pathologic, and radiologic features (1983) (167)
- Model for end‐stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula (2006) (164)
- Complete Resolution of Inflammatory Activity Following Corticosteroid Treatment of HBsAg‐Negative Chronic Active Hepatitis (1984) (155)
- High Mean Fluorescence Intensity Donor‐Specific Anti‐HLA Antibodies Associated With Chronic Rejection Postliver Transplant (2011) (155)
- Activation of Tumor Necrosis Factor-α System in Chronic Hepatitis C Virus Infection (1997) (151)
- Randomized trial of chlorambucil for primary biliary cirrhosis. (1986) (148)
- Intrahepatic hepatitis C virus–specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C (1998) (148)
- Long‐term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation (2012) (146)
- Anti–Interleukin‐2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation (2001) (144)
- Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C (2004) (138)
- Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. (1994) (134)
- Treatment of chronic hepatitis C in active drug users. (2001) (133)
- Prediction of response to interferon treatment of chronic hepatitis C. (1994) (132)
- Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. (1999) (132)
- Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation (2009) (132)
- Response to higher doses of interferon alfa‐2b in patients with chronic hepatitis C: A randomized multicenter trial (1996) (130)
- Interferon in viral hepatitis: Role in pathogenesis and treatment (1986) (126)
- A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. (2020) (123)
- Discrepancy between biochemical and virological responses to interferon-α in chronic hepatitis C (1993) (123)
- Economic model of a birth cohort screening program for hepatitis C virus (2012) (122)
- Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. (1983) (121)
- Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin (2002) (118)
- Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. (1997) (116)
- Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions (1987) (114)
- Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. (2010) (114)
- Reactivation of chronic type B hepatitis presenting as acute viral hepatitis. (1985) (113)
- Interleukin-1 differentially modulates chondrocyte expression of cyclooxygenase-2 and phospholipase A2. (1993) (111)
- Autoimmune Features as Determinants of Prognosis in Steroid-Treated Chronic Active Hepatitis of Uncertain Etiology (1983) (108)
- Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. (1997) (107)
- Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C (1996) (101)
- Hepatitis C virus genotypes and quasispecies. (1999) (101)
- Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C (2002) (100)
- Hepatitis C virus infection in kidney transplant recipients (1993) (99)
- Transforming growth factor‐ß1 in chronic hepatitis C (1997) (95)
- Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. (2011) (94)
- A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C (2011) (92)
- Pilot study of recombinant human α-interferon for chronic type B hepatitis (1986) (88)
- Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. (2008) (86)
- The interferon system in acute and chronic viral hepatitis. (1986) (85)
- Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. (1994) (80)
- Effects of recombinant interleukin-1 beta on phospholipase A2 activity, phospholipase A2 mRNA levels, and eicosanoid formation in rabbit chondrocytes. (1989) (79)
- Interleukin-1 beta stimulates phospholipase A2 mRNA synthesis in rabbit articular chondrocytes. (1989) (77)
- Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial (1990) (76)
- Long-Term Consequences After Jejunoileal Bypass for Morbid Obesity (1998) (74)
- Effects of influenza virus vaccine on hepatic drug metabolism (1985) (71)
- Limiting Hepatitis C Virus Progression in Liver Transplant Recipients Using Sirolimus‐Based Immunosuppression (2011) (71)
- Transforming growth factor-beta 1 in chronic hepatitis C. (1997) (67)
- Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis (1994) (66)
- Improved results of transplantation for hepatocellular carcinoma: A report from the international registry of hepatic tumors in liver transplantation (2009) (63)
- Treatment of chronic hepatitis C (1997) (63)
- Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon. (1985) (63)
- Current therapy for chronic hepatitis C. (2000) (61)
- Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C (2003) (60)
- Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection (2003) (58)
- Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. (1983) (58)
- Recombinant α-interferon treatment of non-A, non-B (type C) hepatitis : review of studies and recommendations for treatment (1990) (57)
- Reactivation of chronic hepatitis B virus infection. (1987) (57)
- Optimization for the detection of hepatitis C virus antigens in the liver. (1994) (57)
- A Phase I/II Study Evaluating Escalating Doses of Recombinant Human Albumin-Interferon-α Fusion Protein in Chronic Hepatitis C Patients who have Failed Previous Interferon-α-Based Therapy (2006) (57)
- Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis (1984) (55)
- Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. (2001) (53)
- A psychometric normative database for pre-liver transplantation evaluations. The Florida cohort 1991-1996. (1999) (52)
- Fibrosing cholestatic hepatitis in a transplant recipient with hepatitis B virus precore mutant. (1993) (51)
- Significance of antibody to the host cellular gene derived epitope GOR in chronic hepatitis C virus infection. (1993) (50)
- The Healthcare Burden Imposed by Liver Disease in Aging Baby Boomers (2010) (49)
- Acute type A hepatitis during chronic hepatitis B virus infection: Association of depressed hepatitis B virus replication with appearance of endogenous alpha interferon (1984) (48)
- Hepatic expression of hepatitis C virus RNA in chronic hepatitis C: A study by in situ reverse‐transcription polymerase chain reaction (1996) (48)
- Fluid homeostasis after heart transplantation: the role of cardiac denervation. (1996) (48)
- Breakdown of blood pressure and body fluid homeostasis in heart transplant recipients. (1996) (46)
- Conivaptan increases serum sodium in hyponatremic patients with end‐stage liver disease (2009) (46)
- Clinical predictors of response to recombinant interferon‐α treatment in patients with chronic non‐A, non‐B hepatitis (hepatitis C) (1994) (44)
- Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. (2009) (43)
- Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. (1993) (41)
- Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient. (1994) (41)
- Characterization of a cDNA encoding rat sterol carrier protein2. (1990) (41)
- Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin. (2000) (40)
- Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. (2000) (40)
- Immunologic effects of interferon-alpha in man: treatment with human recombinant interferon-alpha suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis. (1986) (39)
- Interferon treatment of chronic hepatitis C. (1994) (36)
- Combination treatment with interferon and ribavirin for chronic hepatitis C. (1999) (36)
- Long-Term Follow-Up of Liver Transplantation for Budd-Chiari Syndrome With Antithrombotic Therapy Based on the Etiology (2011) (35)
- Intrathoracic extension of retroperitoneal urine collections. (1981) (35)
- Interferon treatment of viral hepatitis in immunocompromised patients. (1989) (35)
- Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. (1982) (35)
- Acquired hepatocerebral degeneration: MR similarity with Wilson disease. (1988) (33)
- Transfer of hepatitis B virus by contaminated reusable needle electrodes after electrodesiccation in simulated use. (1986) (32)
- Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens (2007) (32)
- Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. (1984) (31)
- Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. (1986) (31)
- An outcome comparison between primary liver transplantation and retransplantation based on the pretransplant MELD score (2006) (31)
- Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group. (1990) (30)
- A charged amino acid substitution within the transmembrane anchor of the Rous sarcoma virus envelope glycoprotein affects surface expression but not intracellular transport (1987) (30)
- Chronic hepatitis C and liver transplantation. (2004) (30)
- α-Glutathione S-Transferase as a Marker of Hepatocellular Damage in Chronic Hepatitis C Virus Infection (1995) (30)
- Modulation of hepatitis C virus quasispecies heterogeneity by interferon‐α and ribavirin therapy (1997) (28)
- Psychological adjustment of liver transplant candidates. (1993) (28)
- A microplate assay specific for the enzyme aggrecanase. (2003) (27)
- A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. (2006) (27)
- Future options for the management of hepatitis C. (1999) (27)
- Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. (1999) (27)
- Therapy for chronic hepatitis C. (1994) (26)
- Effect of interferon-alpha and ribavirin therapy on serum GB virus C/hepatitis G virus (GBV-C/HGV) RNA levels in patients chronically infected with hepatitis C virus and GBV-C/HGV. (1997) (26)
- Purification and characterization of recombinant plasminogen activator inhibitor-1 from Escherichia coli. (1990) (26)
- Portal hypertension secondary to a spontaneous splenic arteriovenous fistula: case report and review of the literature. (1986) (25)
- Treatment of chronic type B hepatitis with multiple ten‐day courses of adenine arabinoside monophosphate (1985) (25)
- Detection of GB Virus‐C/Hepatitis G Virus RNA in Serum by Reverse Transcription Polymerase Chain Reaction (1997) (24)
- The Prevalence of Hepatitis C Virus Infection in Texas: Implications for Future Health Care (2005) (23)
- Impact of Birth Cohort Screening for Hepatitis C (2014) (22)
- Detection of hepatitis C virus genome in formalin‐fixed paraffin‐embedded liver tissue by in situ reverse transcription polymerase chain reaction (1994) (22)
- Hepatitis C virus: a critical appraisal of approaches to therapy. (2009) (21)
- Detection of hepatitis C viral sequences in formalin‐fixed, paraffin‐embedded liver tissue: Effect of interferon alpha therapy (1994) (21)
- Detection of hepatitis c virus rna genome in liver tissue by nonisotopic in situ hybridization (1994) (21)
- High-dose angiotensin-converting enzyme inhibition restores body fluid homeostasis in heart-transplant recipients. (2003) (20)
- Post–liver transplant survival in hepatitis C patients is improving over time (2009) (20)
- Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis (1998) (20)
- Future trends in hepatology: Challenges and opportunities (2008) (20)
- The incidental focal liver lesion: Photon, proton, or needle? (1998) (20)
- Variations of hepatitis B virus core gene sequence in Western patients with chronic hepatitis B virus infection (1997) (20)
- Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group. (1994) (20)
- Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection. (1995) (19)
- 113 A phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon-based therapy for chronic hepatitis C infection (2006) (19)
- Tumor biology and pre‐transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation (2013) (19)
- Interferon-prednisone therapy for hepatitis B (1990) (19)
- Management of ascites in patients with end-stage liver disease. (2004) (18)
- Recombinant alpha-interferon treatment of non-A, and non-B (type C) hepatitis: review of studies and recommendations for treatment. (1990) (18)
- Treatment of chronic hepatitis C infection: one step at a time. (2005) (18)
- Treatment of acute and chronic hepatitis C. (1997) (18)
- Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients (2013) (17)
- Utilization of hepatitis C antibody‐positive livers: genotype dominance is virally determined (2012) (17)
- Plasma glutathione concentration in patients with chronic hepatitis C virus infection (1995) (17)
- Current treatment for chronic hepatitis C. (2001) (17)
- Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: Chasing windmills? (2006) (16)
- Relationship between the presence of circulating anti-GOR and hepatitis C viremia/genotype. (1995) (14)
- 1406 ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR (2012) (14)
- Managing chronic hepatitis C virus infection. (1993) (12)
- The evolving treatment of chronic hepatitis C: where we stand a decade out. (2004) (12)
- A yeast genetic assay for caspase cleavage of the amyloid-β precursor protein (2000) (12)
- Induction of erythrocyte HLA expression during interferon treatment and HIV infection. (1990) (12)
- Review: Hepatitis C virus replication and potential targets for direct-acting agents (2010) (12)
- NON‐A, NON‐B HEPATITIS AND ELEVATED SERUM AMINOTRANSFERASES IN RENAL TRANSPLANT PATIENTS: CORRELATION WITH HEPATITIS C INFECTION (1993) (11)
- RELATIONSHIP OF THE POLYMERASE CHAIN REACTION FOR CYTOMEGALOVIRUS TO THE DEVELOPMENT OF HEPATITIS IN LIVER TRANSPLANT RECIPIENTS (1993) (11)
- Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy. (1997) (11)
- Durability of viral response to interferon ribavirin combination in patients with chronic hepatitis C (2001) (11)
- Immunoglobulin M and A antibodies to hepatitis C core antigen in chronic hepatitis C virus infection (1994) (11)
- Tailoring antiviral therapy in hepatitis C (2006) (11)
- Hepatitis C virus antibody in patients with chronic autoimmune hepatitis: pitfalls in diagnosis and implications for treatment. (1991) (11)
- The challenge of progressive hepatitis C following liver transplantation (2006) (11)
- Should we test hepatitis C virus genotype and viraemia level in patients with chronic hepatitis C? (1997) (10)
- Hepatitis G virus infection in renal transplant recipients (1999) (10)
- New schedules of interferon for chronic hepatitis C. (1999) (10)
- New approaches and therapeutic modalities for the prevention and treatment of recurrent HCV after liver transplantation (2003) (9)
- Treatment of chronic hepatitis. (1992) (9)
- Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C (1995) (9)
- Treatment of chronic hepatitis B (1991) (9)
- COMPARISON OF SNAKE VENOM REPROLYSIN AND MATRIX METALLOPROTEINASES AS MODELS OF TNF-α CONVERTING ENZYME (1997) (8)
- Variations of hepatitis C virus NS5B sequence (nucleotides 8261–8566) do not correlate with response to interferon‐α therapy (1995) (8)
- Effects of recombinant human leukocyte interferon treatment of endogenous interferon production in patients with chronic type-B hepatitis. (1986) (8)
- Gaucher's disease in a patient with chronic active hepatitis. (1986) (8)
- alpha-Glutathione S-transferase as a marker of hepatocellular damage in chronic hepatitis C virus infection. (1995) (8)
- Modeling therapeutic benefit in the midst of uncertainty (1996) (7)
- Update on the management of chronic hepatitis B. (2002) (7)
- Essays From the Field. (2003) (7)
- Clinical trial: interferon alpha‐2b continuous long‐term therapy vs. repeated 24‐week cycles for re‐treating chronic hepatitis C (2007) (7)
- 146 A more severe hepatitis C recurrence (HCVR) post liver transplantation (OLT) observed in recent years may be explained by the use of lower-dose corticosteroid (CS) maintenance protocols (2003) (7)
- Hepatitis C Virus Infection—Pathobiology and Implications for New Therapeutic Options (2007) (6)
- Hepatitis non A, non B. Manifestations and implications of acute and chronic disease. (1982) (6)
- Advances in liver disease. Highlights from the 51st Annual Meeting of the American Association for the Study of Liver Diseases, October 27-31, 2000, Dallas, TX. (2001) (6)
- Interferon-alpha therapy exerts selective pressure on hepatitis C virus quasispecies equilibrium. (1999) (6)
- Clinical vignettes in geriatric depression. (2011) (6)
- Hepatitis C virus infection among health care workers. (1996) (5)
- Effect of Tacrolimus on Survival in Hepatitis C–Infected Patients After Liver Transplantation (2011) (5)
- Hepatitis C screening: summary of recommendations from the clinical decision tool. (2013) (5)
- New therapies: oral inhibitors and immune modulators. (2006) (4)
- Interferon treatment of cirrhotic patients with chronic hepatitis C: a logical intervention. (1994) (4)
- Chronic type B hepatitis: clinical course. (1983) (4)
- Current status of interferon therapy for chronic hepatitis C: a hepatologist's perspective. (1993) (4)
- Initial results with recombinant interferon alfa-2b in patients with chronic hepatitis C: the United States experience. (1993) (4)
- High-level synthesis of biologically active human plasminogen activator inhibitor type 1 (PAI-1) in Escherichia coli. (1990) (4)
- Treatment of Chronic Hepatitis C Infection (2002) (3)
- Best of the AASLD. Highlights from the 52nd Annual Meeting of the American Association for the Study of Liver Diseases. November 9-13, 2001, Dallas, TX. (2002) (3)
- Thoughts on nutrition and liver disease. (2006) (3)
- Evaluating rapid virological response reduces ribavirin and peginterferon alfa-2B treatment costs for chronic hepatitis C in the United Kingdom (2003) (3)
- Th2 cytokine profile in chronic hepatitis C (1995) (3)
- Renal-Sparing Immunosuppressive Protocol Using Okt3 After Liver Transplantation: A 19-Year Single-Institution Experience (2011) (3)
- Genomic variation of hepatitis C virus: clues to clinical variation? (1992) (3)
- 1421 ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS) (2013) (3)
- Therapy of Digestive Disorders (2006) (3)
- Hepatitis B and C: influence of immunosuppression. (1993) (3)
- Interferon therapy for chronic hepatitis C. (1996) (2)
- Use of protease inhibitors in liver transplant recipients. (2012) (2)
- Hepatitis B virus replication in steroid-treated severe HBsAg-positive chronic active hepatitis (1985) (2)
- Essays From The Field: Behavioral Healthcare In Rural And Frontier Areas: An Interdisciplinary Handbook (2003) (2)
- Treatment of chronic hepatitis C. (1997) (2)
- Interferon alfa and ribavirin for orthotopic liver transplant recipients with recurrent hepatitis C (2000) (2)
- 9 – Natural History of Hepatitis C (2005) (2)
- Treatment of chronic hepatitis C: Improved combination therapy (2003) (2)
- Post-transplantation (LT) significant HCV-related disease severity: Increase in recent years (2000) (2)
- MMPI Profiles of Liver and Heart Transplant Candidates With and Without Significant Histories of Heavy Alcohol Use (1998) (2)
- Assessment of Stress in Research and Clinical Settings (2007) (2)
- Radiosurgery in the Treatment of Unresectable Hepatocellular Cancer and as a Bridge to Transplantation (2009) (1)
- Current and Future Therapy of Chronic Hepatitis C (2009) (1)
- CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Ascitic Fluid Lactoferrin for Diagnosis of Spontaneous Bacterial Peritonitis (2008) (1)
- Hepatitis B: diagnosis and treatment. (1997) (1)
- HIV-induced HBV breakthrough during interferon-alpha therapy. (1993) (1)
- Current concepts in the diagnosis and management of hepatitis B surface antigen-positive chronic active hepatitis. (1981) (1)
- Optimization for the detection of hepatitis C viral (HCV) antigens in liver. (1993) (1)
- Treatment of unresectable hepatocellular carcinoma. (1995) (1)
- Serology of acute and chronic type B hepatitis. (1989) (1)
- Loss of HBsAg after interferon‐α treatment: Cure of chronic hepatitis B virus? (1991) (1)
- Is peginterferon alfa-2B plus ribavirin cost-effective for treating chronic hepatitis C in the United Kingdom? (2003) (1)
- Treatment of chronic hepatitis C: Impact of combination therapy (1999) (1)
- Monitoring of viral levels during therapy of hepatitis C (2002) (1)
- New schedules of intederon for chronic hepatitis C (1999) (0)
- FACTORS AFFECTING RECURRENCE OF HEPATITIS C AFTER LIVER TRANSPLANTATION—CORRELATION WITH HISTOLOGY ON PROTOCOL LIVER BIOPSIES.: 1910 (2010) (0)
- 6.3-02 Effect of viral infections and interferon on erythrocyte, plasma and platelet HLA (1989) (0)
- , standard genotyping methodologies . hepatitis C virus : strong correlation with Evaluation of a novel serotyping system for (1995) (0)
- Interferon-α Therapy Exerts Selective Pressure on Hepatitis C Virus Quasispecies Equilibrium (1999) (0)
- Heart Failure/Cardiac Transplantation High-Dose Angiotensin-Converting Enzyme Inhibition Restores Body Fluid Homeostasis in Heart-Transplant Recipients (2003) (0)
- The association of HLA haplotypes in liver transplant donors and recipients on biochemical and histologic recurrence of hepatitis C (2000) (0)
- Chronic hepatitis B responds to interferon alfa-2b, study shows (1991) (0)
- Book reviews (2005) (0)
- Acknowledgment of 2008 Reviewers (2009) (0)
- Managing complications of cirrhosis. (2002) (0)
- The Impact of Birth-Cohort Screening for Hepatitis C Virus (HCV) Compared With Current Risk-Based Screening on Lifetime Incidence of and Mortality From Advanced Liver Disease (AdvLD) in the United States (U.S.) (2011) (0)
- Liver transplantation at the University of Florida. (1994) (0)
- Associated Conditions in Chronic Hepatitis (1989) (0)
- Hepatitis D Virus (2003) (0)
- Gary L. Davis, MD: A Conversation with the Editor (2003) (0)
- Hepatitis C virus (1995) (0)
- Update on the Treatment of Chronic Hepatitis C (2005) (0)
- HCV and Chemotherapy: Does Infection Change Management? (2012) (0)
- Monitoring of Viral Levels of Hepatitis During Therapy (2005) (0)
- Current and Future Therapy for Hepatitis B and C (2009) (0)
- Chapter 79 – Recurrent Hepatitis C After Transplantation (2015) (0)
- Best of DDW 2004: Highlights from the 2004 Digestive Disease Week (2004) (0)
- Hepatitis C and G (1998) (0)
- Hepatitis C virus. Edited by H. W. Reesink. 212 pp. Basel: Karger Publishers, 1994. $193.75 (1995) (0)
- Emerging Hepatitis Viruses (2003) (0)
- Hepatic sarcoidosis presenting as acute abdominal pain. (1994) (0)
- Loss of HBsAg after interferon-alpha treatment: cure of chronic hepatitis B virus? (1991) (0)
- Humoral immunoreactivity to HCV core antigen in patients with chronic hepatitis C. (1997) (0)
- Chapter 35 – Impact of interferon alpha-2b and of combination with ribavirin on progression of liver fibrosis in patients with chronic hepatitis C (2003) (0)
- 121Marked increase in post-transplantation (LT) HCV-related fibrosis progression in recent years (2000) (0)
- Reply (2003) (0)
- Rapid publication Significance of antibody to the host cellular gene derived epitope GOR in chronic hepatitis C virus infection (1993) (0)
- Book Reviews (1975) (0)
- Epidemiology of Chronic HCV (2012) (0)
- CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression (2010) (0)
- Chapter 10 – Natural History of Hepatitis C (2015) (0)
- Interferons return for treatment of chronic hepatitis B. (2005) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gary L. Davis?
Gary L. Davis is affiliated with the following schools:
